Market Overview

UPDATE: Credit Suisse Upgrades Ironwood Pharmaceuticals to Outperform on Positive Linzess Survey

Related IRWD
20 Stocks Which Rallied Three Days On Increasing Volume
BTIG Raises Ironwood Pharmaceuticals Price Target Ahead Of New Drug Launch

Credit Suisse upgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Neutral to Outperform and raised the price target from $15.00 to $24.00.

Credit Suisse analyst Catherine Arnold commented, "CS proprietary market research survey with ~100 physicians implies greater demand via both category expansion and competitive market share. Respondents include 55% gastroenterologists and 45% PCPs, ~70% who were early Linzess users, and all with brand awareness."

Ironwood Pharmaceuticals closed at $17.68 on Thursday.

Latest Ratings for IRWD

Aug 2016BarclaysMaintainsEqual-Weight
Aug 2016JP MorganMaintainsOverweight
Apr 2016Cowen & Co.UpgradesMarket PerformOutperform

View More Analyst Ratings for IRWD
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Analyst Ratings


Related Articles (IRWD)

View Comments and Join the Discussion!